Abstract
Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have